Neoadjuvant chemotherapy (NAC) induces a pathologic complete response (pCR) in approximately 30% of patients with triple-negative breast cancers (TNBC). In patients lacking a pCR, NAC selects a subpopulation of chemotherapy-resistant tumor cells. To understand the molecular underpinnings driving treatment-resistant TNBCs, we performed comprehensive molecular analyses on the residual disease (RD) of 74 clinically-defined TNBCs after NAC including next-generation sequencing (NGS) on 20 matched pre-treatment biopsies. Combined NGS and digital RNA expression analysis identified diverse molecular lesions and pathway activation in drug-resistant tumor cells.
Introduction
Neoadjuvant chemotherapy (NAC) is used increasingly in patients with triplenegative breast cancer (TNBC), a subtype lacking expression of estrogen receptor (ER), progesterone receptor (PR) or human epidermal growth factor-2 (HER2) amplification. The goals of NAC are to increase likelihood of breast-conserving surgery and to eliminate clinically silent micro-metastases. Approximately 30% of TNBC patients who receive NAC achieve a pathological complete response (pCR). These patients have a favorable recurrence-free (RFS) and overall survival (OS) (1) (2) (3) . The remaining patients with residual viable cancer in the breast or lymph nodes exhibit high rates of metastatic recurrence and an overall poor long term outcome(1-3).
Immunohistochemistry (IHC) of the proliferation marker Ki67 in the post-NAC residual disease (RD) has been shown to correlate with patient outcome (4-6).
Previous studies showing the prognostic ability of Ki67 after NAC included all subtypes of breast cancer (i.e. HER2-enriched, luminal A, luminal B and basal-like), which also offer prognostic information (7) (8) (9) . We have recently shown that these subtypes differ vastly in their post-NAC Ki67 scores, confounding the prognostic utility of Ki67 in this setting (10) , and has been confirmed by other investigators (9) . Furthermore, Ki67 scoring is difficult to standardize among clinical laboratories and many studies have defined different 'cutoffs' for patient stratification, ranging from 14-50%(4-6). Finally, the Ki67 scoring of the post-NAC residual tumor is not actionable as it does not identify a pathogenic driver of the tumor and, as such, a drug target and rational treatment decision. Intuition suggests that tumor cells remaining after NAC contain the cancer cell population intrinsically resistant to chemotherapy. These tumor cells likely mirror the micro-metastatic component of the disease that is ultimately responsible for distant metastases, and is unlikely to be highly sensitive to further chemotherapy once clinical metastases become evident. The standard of care for patients with TNBC who have RD after NAC is observation as therapies that would be effective in reducing recurrences are unknown. Thus, we molecularly-profiled the RD remaining after NAC in a cohort of 111 TNBCs (including gene expression analysis of 89 tumors and NGS of 80 tumors, 74 of which were TNBC) to identify lesions that could be therapeutically targeted in adjuvant trials.
Results

Ki67 does not predict clinical outcome in TNBCs
Since TNBC is a heterogeneous subtype of breast cancer(11), we determined if Ki67 could predict patient outcome within this clinical subtype by scoring Ki67 in the RD of a cohort of 111 TNBCs after NAC. Patient demographics are listed in Supplementary data, Table 1 . Molecular subtyping based on gene expression using the PAM50 centroids(7) revealed a predominance of tumors with basal-like gene expression (Supplementary data, Figure 1A ). After adjusting for 7 tumors that exhibited HER2 amplification (see below), 70% of TNBCs were basal-like, which is similar to previously published rates in larger datasets (12) . Basal-like status was associated with a trend toward worse RFS and OS (Log-rank p=0.12 and p=0.058, respectively; Supplementary data, Figure 1B) . As we have previously demonstrated (10) , the Ki67 score in the RD Figure 1F ). Tumor cellularity was significantly decreased between the pre and post-NAC samples (paired t-test p<0.0001) (Supplementary data, Figure 1G ). Node status at surgery (an established prognostic marker), but not a change in Ki67, was predictive of both RFS and OS, although this effect appeared to be confined only to postmenopausal women (Supplementary data, Fig 2) . These data suggest that the underlying molecular subtype may confound the prognostic ability of Ki67 score in the RD after NAC.
Genomic alterations in drug-resistant residual cancers after NAC
To identify targetable molecular lesions present in breast cancers after NAC, we evaluable NGS data, 68 of which also had CNA data. No obvious differences between the NGS-evaluable population and the entire cohort were observed in terms of outcome or clinical characteristics. NGS analysis revealed a diversity of lesions, many of which were present in less than 5% of samples ( Figure 1A and Supplementary data, Table 3 ).
Alterations in TP53 were identified in 72/81 (89%), which is similar to other studies of basal-like or TNBC including The Cancer Genome Atlas (TCGA) dataset (~85%) (13, 14) . The next most common alterations included MCL1 (54%) and MYC (35%) gene amplifications. MYC amplifications were detected primarily in basal-like tumors (42% basal vs. 10% all others; Fisher's exact p=0.018) and with a similar frequency as in the basal-like cohort in the TCGA (Supplementary data, Table 4 ).
Compared to basal-like primary tumors in the TCGA, we detected a higher frequency of MCL1 amplifications (54% in post-NAC TNBC vs. 19% in TCGA basal-like tumors; p=0.0006), PTEN deletions or mutations (trend, p=0.0697) and JAK2 amplifications (trend, p=0.08) in the RD. Amplifications in CDK6 and CCND1-3 were collectively enriched as well (24% in post-NAC TNBC vs. 10% in TCGA basal-like tumors). This difference suggests that these alterations are present at higher frequency in chemotherapy-treated TNBCs, and may play a role in de novo or acquired therapeutic resistance. However, it is important to note that these comparisons of copy-number alterations with the TCGA data are made between platforms (NGS versus Affymetrix SNP arrays), and thus some variation in calling rates and detection of alterations may be platform-specific. Figure 1B) . Importantly, over 90% of patients had alterations in at least one of these clinically targetable pathways.
Gene expression analysis
NanoString gene expression analysis was performed in 104/111 samples; 89 samples (86%) passed quality control metrics (Supplementary data, Table 5 ). Sixty-five samples were analyzed by both NGS and NanoString. Overall, 450 transcripts were quantified. These 450 transcripts were selected based on their inclusion in published gene expression signatures or based on their association with the post-NAC Ki67 score we reported recently (15) . Specifically, we included the PAM50 genes (7), a signature of MEK activation (16) , a signature of TGFȕ activation (17) and genes we have previously shown to correlate with the post-NAC Ki67 score (10) . These signatures were selected based on our previous studies demonstrating association of DUSP4 loss with the MEK activation signature, and with the enrichment of TGFȕ inducible genes after NAC (15, 18) . There was excellent concordance between gene expression and CNAs or mutations in cases where both were assessed (Supplementary data, Figure 3 ).
Gene expression data were utilized to predict the molecular subtype using the PAM50 centroids. Of the 89 samples, 10 were predicted to be of the luminal subtype. These Table 6 ). Tumor cellularity in the gross specimen appeared to be a defining factor of these clusters, where cluster II represented the most paucicellular tumors with the lowest Ki67 staining ( Figure 1D ). Importantly, the cellularity was less of a defining feature after considering the cellularity of the 'hotspot' regions that were macrodissected for gene expression analysis. Thus, the gene expression patterns may be influenced by tumor sampling but could also be reflective of the underlying microenvironment resulting from a strong anti-tumor effect from neoadjuvant therapy.
Clusters I and III appeared more similar in terms of cellularity and Ki67 staining ( Figure   1D ). However, Cluster I had a distinct lack of expression of TGFȕ-responsive genes. Cluster III had a high MEK signature score. This cluster contained a group of tumors with low expression of DUSP4, a negative-regulator of the MAPK pathway, offering at least one possible mechanism of MEK activation ( Figure 1D ). Importantly, survival of the patients comprising these clusters was not significantly different (data not shown).
Bioinformatic exploration of these genesets with the Molecular Signatures Database (http://www.broadinstitute.org/gsea/msigdb) suggested that Cluster I was driven primarily by luminal-like breast expression patterns (Supplementary Data, Table   7 ), despite a lack of ER, PR, or AR IHC staining in these tumors. Furthermore, several overlapping gene signatures suggested that tri-methylated H3K27 (H3K27me3) genes were highly expressed in this cluster. H3K27me3 maintains epigenetic silencing of developmental genes in stem cells, leaving them poised for expression upon differentiation (20) . Thus, we speculate Cluster I is composed of more differentiated tumors, with high Ki67 and low TGFȕ and MEK activity. In contrast, Cluster IIIexpressed genes overlapped with invasive signatures across many types of cancer, including signatures of poorly-differentiated cancers, suggesting that this cluster reflects tumors maintained in a less differentiated state and toward a higher stem-cell like hierarchy. The expression patterns in cluster III, reflective of high MEK and TGF-ȕ activation (including tumors with DUSP4 loss), are consistent with stem-like phenotypes induced by these pathways, as we have previously demonstrated (15, 18, 21) .
Selection of oncogenic alterations by chemotherapy
In order to quantify enrichment of alterations during NAC, we analyzed 20 matched pre-treatment biopsies by NGS. We detected gain (not detected in pre- cohort relative to primary tumors in the TCGA, this discordance suggests MCL1 amplification may be associated with de novo resistance to chemotherapy, but is not enriched further upon treatment.
Co-amplification of MYC and MCL1 in the RD of TNBC
The anti-apoptosis MCL1 protein is dynamically regulated during cell cycle progression and shows rapid turnover rates in cancer cells (22). To determine whether MCL1 CNAs contribute to higher protein levels in breast cancer, we performed IHC for MCL1 on tissue microarrays (TMAs) of this cohort. MCL1 amplification was significantly associated with increased protein expression (p=0.01; Figure 3A -B). However, MCL1 amplification does not appear to be the sole factor in modulating protein expression in breast cancer, as several samples showed high MCL-1 protein levels by IHC in the absence of CNAs. We also detected 3 frameshift or nonsense mutations in FBXW7, the E3 ubiquitin ligase responsible for targeting MCL-1 (and MYC) for proteasome-mediated degradation (23). However, presence of these mutations was not associated with higher protein levels of MCL-1 ( Figure 3A ).
We detected a high degree of concordance between CNAs in both MYC and MCL1. MCL1 expression has been shown to facilitate MYC-induced lung cancers and leukemogenesis(24-26), although this interaction has not been shown in breast cancer.
Indeed, 83% of MYC amplified tumors also showed CNAs at MCL1 (p=0.001; Figure   3C ). Co-occurence of MYC and MCL1 amplification was not associated with altered prognosis (RFS or OS) compared to patients with amplification of either gene alone in this dataset (data not shown). This co-occurrence was also present in the basal-like Resistance to doxorubicin was mediated in part by decreased baseline and doxorubicinmediated apoptosis ( Figure 3K ). Thus, MYC and MCL1 enhance cell fitness, and MCL1 additionally protects TNBCs from chemotherapy-induced apoptosis.
Molecular alterations in the RD after NAC correlate with patient outcome
Research. (16) predicted poor RFS and OS (P=0.059; HR=1.758 and P=0.013; HR=2.264, respectively). These data offer insights into molecular alterations that may predict the natural history of TNBC after NAC.
Prognostic interaction of MEK activation and MYC amplification
MYC amplifications in the RD trended toward an association with poor OS, while high MEK transcriptional output was a risk factor for reduced RFS and OS. Importantly, the Ras/MAPK pathway has been shown to cooperate with the MYC oncogene (27, 28).
Thus, we tested the possibility that these perturbations may interact with one another.
When the interaction term was tested by Cox proportional hazards analysis, a significant interaction was noted for RFS but not for OS (P=0.03 and p=0.83, respectively). Kaplan-Meier analysis confirmed this association ( Figure 4A-C Figure 6C-D) . These data suggest that MYC cooperates with Ras/MAPK to drive anchorage-independent growth in breast cancer.
Molecular profiling for rational selection of adjuvant targeted therapies
Despite the high likelihood of recurrence, the current standard of care for patients with TNBC who do not achieve a pCR after NAC is watchful waiting. Patients who recur with metastatic cancer are less likely to exhibit prolonged responses to conventional anti-cancer therapy, since the micrometastases that generated these clinical recurrences have already been exposed to chemotherapy in the neoadjuvant setting.
Research. 
This unmet need suggests the identification of actionable molecular targets in the RD could, in turn, be explored in adjuvant trials after NAC and mastectomy. Since the spectrum of alterations present in such tumors is highly diverse, we integrated existing preclinical and clinical data into an 'actionability' table of rational therapies for the identified alterations (Table 2 and Supplementary data, Table 6 ).
Of note, we detected two tumors (2.5%) with presumed loss of function alterations in TSC1: a truncation of an intergenic region between intron 8 and the 3'UTR contained in the 23 rd intron (Supplementary data, Figure 7 ) which was detected in matched pre-and post-NAC samples in one patient, and a nonsense mutation (TSC1_Q516*, 20% allele frequency) in another patient (Supplementary data, Table 2 ).
Loss of TSC1 function has been proposed as a basis for significant clinical responses in metastatic bladder cancer to the TORC1 inhibitor everolimus (37) , and may also represent a therapeutically actionable target in patients with breast cancer. Importantly, loss of function TSC1 deletions, truncations or nonsense mutations were not identified in the TCGA breast cancer study (13, 38).
Discussion
Herein, we have described the genomic landscape of drug-resistant tumor cells remaining in the breast of patients with TNBC after anti-cancer chemotherapy. We also performed serial analysis to detect changes in CNAs and mutations before and after NAC. These data provide insights into genomic alterations which may predict de novo or acquired resistance to standard anti-cancer therapies in TNBC and could inform on the effective use of rational molecularly targeted agents in adjuvant trials. In an effort to
not confound our results with tumors with variable residual cancer burden (RCB), we focused on a cohort of cancers with significant macroscopic residual disease after NAC.
Indeed, this represents a cohort with a particularly poor prognosis (median survival ~18 months).
Several molecular insights were gained through this analysis. We showed that the Ki67 score after NAC does not provide prognostic information in patients with TNBC. Further, we confirmed our previous report demonstrating that Ki67 in the RD is intimately related to the underlying molecular subtype (15) . We also found frequent coamplification of MCL1 and MYC which conferred an advantage in anchorageindependent growth. Importantly, these co-amplifications were more frequent in this study compared to those previously reported in primary basal-like breast tumors. Overall, this analysis provides new information on the molecular alterations present in chemotherapy-resistant tumor cells within TNBCs. As supported by the poor outcome of patients with TNBC that recur with metastatic disease after an incomplete response to NAC, we surmise these persistent tumor cells are resistant to conventional cytotoxic chemotherapies without the addition of novel agents targeting these oncogenic pathways. Further, these data suggest that molecular analysis of TNBCs not achieving a pCR to NAC should be performed routinely in order to stratify patients according to this information to rational adjuvant trials with molecularly targeted agents.
Materials and methods:
Patients and tumor specimens. Gene expression analyses. RNA was isolated from FFPE tumor blocks by macrodissecting tumor-rich regions from 3-6 10-μm sections. RNA was purified using the RNEasy FFPE kits (Qiagen). Gene expression analysis was performed by NanoString as previously described (10) . Raw transcript counts were subtracted from background (negative input control). Normalization of raw transcript counts was performed by dividing by the geometric mean of 7 housekeeper-control genes; NPAS1, NAGA, POLR1B, CD40, WAS, B2M, and TUBB. Housekeeper-normalized transcript counts were log2 transformed and data were row z-score standardized prior to further analysis. PAM50 analysis was performed using the PAM50 qRT-PCR centroids(7) on the normalized log2 gene expression data prior to z-standardization.
Research. was performed using the HiSeq2000 (Illumina). Sequence data from genomic DNA were mapped to the reference human genome (hg19) using the BWA aligner(42). PCR duplicate read removal and sequence metric collection was performed using Picard (http://picard.sourceforge.net) and SAMtools (43) . Local alignment optimization was performed using GATK(44).
Genomic alteration detection. Base substitution detection was performed using a Bayesian methodology, which allows detection of somatic mutations at a low mutation allele frequency (MAF) and increased sensitivity for mutations at hotspot sites (45) through the incorporation of tissue-specific prior expectations:
‫݊݅ݐܽݐݑܯ‪ܲሺ‬‬ ‫‪ȁ‬ݐ݊݁ݏ݁ݎ‬ ܴ݁ܽ݀ ‫ܽݐܽ݀‬ ̶̶ܴሻ ൌ ‫ݕܿ݊݁ݑݍ݁ݎܨ‪ܲሺ‬‬ ‫݂‬ ‫݊݅ݐܽݐݑ݉‬ ̶ ̶ Ͳȁܴሻ ‫ן‬ ͳ െ ܲሺܴȁ‫ܨ‬ ൌ Ͳሻܲሺ‫ܨ‬ ൌ Ͳሻ, where ܲሺܴȁ‫ܨ‬ሻ is evaluated with a multinomial distribution of the observed allele counts using empirically observed error rates and ܲሺ‫ܨ‬ ൌ Ͳሻ is the prior expectation of mutation in the tumor type. To detect indels, de novo local assembly in each targeted exon was performed using the de-Bruijn approach (46) . Candidate calls are filtered using a series of quality metrics, including strand bias, read location bias and a custom database of sequencing artifacts derived from normal controls. Germline Immunoblotting. Immunoblotting was carried out as described 43 
